Accessibility Menu
 
Cosmo Pharmaceuticals logo

Cosmo Pharmaceuticals

(OTC) CMOPF

Current Price$98.70
Market Cap$1.72B
Since IPO (2017)-34%
5 Year+22%
1 Year+104%
1 Month-2%

Cosmo Pharmaceuticals Financials at a Glance

Market Cap

$1.72B

Revenue (TTM)

$371.03M

Net Income (TTM)

$129.63M

EPS (TTM)

$-0.25

P/E Ratio

-417.07

Dividend

$4.81

Beta (Volatility)

0.17 (Low)

Price

$98.70

Volume

1,237

Open

$106.00

Previous Close

$106.02

Daily Range

$98.70 - $106.60

52-Week Range

$55.00 - $169.90

CMOPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cosmo Pharmaceuticals

Industry

Pharmaceuticals

Employees

324.5

CEO

Giovanni di Napoli, MBA

Headquarters

Dublin, 2, IE

CMOPF Financials

Key Financial Metrics (TTM)

Gross Margin

49%

Operating Margin

-5%

Net Income Margin

-3%

Return on Equity

-75%

Return on Capital

-1%

Return on Assets

-1%

Earnings Yield

-0.24%

Dividend Yield

4.54%

Payout Ratio

-8.99%

Stock Overview

Market Cap

$1.72B

Shares Outstanding

16.19M

Volume

1.24K

Avg. Volume

385.81

Financials (TTM)

Gross Profit

$48.77M

Operating Income

$10.48M

EBITDA

$2.36M

Operating Cash Flow

$11.61M

Capital Expenditure

$4.23M

Free Cash Flow

$15.84M

Cash & ST Invst.

$122.63M

Total Debt

$4.26M

Cosmo Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$52.52M

+6.9%

Gross Profit

$24.44M

-14.7%

Gross Margin

46.53%

N/A

Market Cap

$1.72B

N/A

Market Cap/Employee

$5.35M

N/A

Employees

321

N/A

Net Income

$1.60M

+75.0%

EBITDA

$2.19M

-61.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$118.37M

+144.4%

Accounts Receivable

$25.59M

-10.1%

Inventory

$10.42M

-26.6%

Long Term Debt

$3.55M

+277.1%

Short Term Debt

$708.23K

-21.0%

Return on Assets

-0.59%

N/A

Return on Invested Capital

-0.98%

N/A

Free Cash Flow

$14.26M

-187.8%

Operating Cash Flow

$12.70M

-170.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TCNNFTrulieve Cannabis Corp.
$9.18-4.28%
GNTLFGenetic Technologies Limited
$1.00+0.00%
NPPNYNippon Shinyaku Co., Ltd.
$8.15+0.00%
LJUIFSSY Group Limited
$0.40+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CNSPCns Pharmaceuticals
$8.93+2.86%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.79+0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$50.85+0.01%
ADTADT
$7.03-0.07%

Questions About CMOPF

What is the current price of Cosmo Pharmaceuticals?

Cosmo Pharmaceuticals is trading at $98.70 per share.

What is the 52-week range for Cosmo Pharmaceuticals?

Over the past 52 weeks, Cosmo Pharmaceuticals has traded between $55.00 and $169.90.

How much debt does Cosmo Pharmaceuticals have?

As of the most recent reporting period, Cosmo Pharmaceuticals reported total debt of $5.01M.

How much cash does Cosmo Pharmaceuticals have on hand?

Cosmo Pharmaceuticals reported $65.61M in cash and cash equivalents in its most recent financial results.

What is Cosmo Pharmaceuticals’s dividend yield?

Cosmo Pharmaceuticals currently has a dividend yield of 4.54%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.